Metformin, bosutinib, and nilotinib activate AMPK activation, which prevents the degeneration of dopaminergic neurons and reduces levels of phosphorylated α-syn Ser129 in Parkinson’s disease and Alzheimer’s disease. This evidence concerns the gene PRKAA1 and Alzheimer disease.